A New York woman has filed a lawsuit against Takeda Pharmaceuticals and Eli Lilly and Co., alleging that the diabetes drug Actos caused her bladder cancer.
The plaintiff began taking Actos (pioglitazone) in May 2003 to help control her blood sugar. She was diagnosed with bladder cancer in March 2007. Her lawsuit alleges that the cancer developed as a result of taking Actos. The suit further claims that the defendants knew that taking the drug for an extended period could increase the risk of bladder cancer but they failed to warn her, her doctor, or other consumers. She is seeking compensation for permanent injuries, emotional distress, and medical and living expenses caused by the cancer diagnosis.
Actos, a Type 2 diabetes medication, was approved by the U.S. Food and Drug Administration (FDA) in 1999. Since Actos has been on the market, a number of research studies have suggested that taking it for longer than one year increases the user’s risk of developing bladder cancer. In 2011, the FDA required Takeda to update the Actos label to warn users of the risk. Plaintiffs in Actos cases have alleged that Takeda was aware of the risks well before the label change was ordered and should have warned them and their doctors.
Parker Waichman LLP filed this lawsuit on the plaintiff’s behalf. The suit is part of a federal multidistrict litigation (MDL) entitled In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the plaintiffs’ steering committee in the Actos MDL.